17,261 trials
Metastatic Pancreatic Adenocarcinoma · Recurrent Pancreatic Adenocarcinoma · Stage IV Pancreatic Cancer AJCC v6 and v7
Primary: Overall Response Rate — 1 Participants
Anxiety
Primary: Change in Recognition Ratings (Positive Interpretation Bias) — 2.40; 2.29; 2.29; 2.30 units on a scale
HIV Infections
Primary: Estimated Threshold of Maternal Steady-state Tenofovir Diphosphate (TFV-DP) Concentration Levels Corresponding to Optimal Adherence in the PK Component — 965; 1050…
Gastric Adenocarcinoma · Esophagogastric Junction · Gastric Cancer
Primary: Overall Survival (OS) — 11.96 Months
Breast Cancer
Primary: Efficacy of Pembrolizumab in Combination With Eribulin. — 25 Participants
Alzheimer's Disease
Primary: Change From Baseline in Repeatable Battery for the Assessment of Neurological Status- Delayed Memory Index (RBANS- DMI) at Week 13 — 10.1; 9.9; 9.7 scores on a scale
Hypertension
Primary: Change From Baseline in Seated Automated Office SBP to Day 85 — -9; -13; -9 mmHg — p==0.135
Chronic Obstructive Pulmonary Disease (COPD)
Primary: Rate of Moderate or Severe COPD Exacerbations in Participants With Moderate to Very Severe COPD. — 1.75; 2.11 exacerbations per year — p=0.1042
Atopic Dermatitis
Primary: Achievement of 75% Reduction From Baseline in the Eczema Area and Severity Index (EASI 75 Response) at Week 12 (Day 84) — 32.3; 37.4 Percentage (%)
Chronic Obstructive Pulmonary Disease
Primary: Sputum Glucose Concentration — 68.92; 12.2 µM
Sickle Cell Disease
Primary: Mean Change From Baseline in Haemolysis Marker (Indirect Bilirubin) — 24.0; 56.4; 44.0; 31.2 micromoles per liter (umol/L)
PTEN Gene Mutation · PTEN Hamartoma Tumor Syndrome
Primary: Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability], Dropout — 3; 2; 5; 2 Participants
Acute Lymphoblastic Leukemia · BCR-ABL1 Fusion Protein Expression · Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Primary: Event-free Survival Rate (EFS) — 21.3 Months
Depression · Depressive Disorder · Depressive Symptoms
Primary: Montgomery Asberg Depression Rating Scale (MADRS) — -12.8; -12.7 units on a scale
Anatomic Stage IV Breast Cancer AJCC v8 · Estrogen Receptor Positive · HER2/Neu Negative
Primary: Response Rate — 29; 6 Participants